Cadila, India’s fourth largest
healthcare Group and an innovation-led global healthcare provider and IDRI a
Seattle-based non-profit research and product development organization has
collaborated on the production and clinical development of IDRl ‘s visceral
leishmaniasis (VL) vaccine candidate, designed to prevent the deadly parasitic
disease. 0731-664-2300
No comments:
Post a Comment